Dong Wang1, Tobias Deuse1, Mandy Stubbendorff1, Ekaterina Chernogubova1, Reinhold G Erben1, Suzanne M Eken1, Hong Jin1, Yuhuang Li1, Albert Busch1, Christian-H Heeger1, Boris Behnisch1, Hermann Reichenspurner1, Robert C Robbins1, Joshua M Spin1, Philip S Tsao1, Sonja Schrepfer2, Lars Maegdefessel1. 1. From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.). 2. From the Department of Cardiovascular Surgery, TSI-Laboratory (D.W., T.D., M.S., S.S.) and Department of Cardiovascular Surgery (T.D., H.R.), University Heart Center Hamburg, Hamburg, Germany; Department of Cardiovascular Surgery, Cardiovascular Research Center Hamburg (CVRC) and DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (D.W., T.D., M.S., S.S.); Atherosclerosis Research Unit, Department of Medicine, Karolinska Institute, CMM L8:03, Stockholm, Sweden (E.C., S.M.E., H.J., Y.L., A.B., L.M.); Unit of Physiology, Pathophysiology, and Experimental Endocrinology, University of Veterinary Medicine, Vienna, Austria (R.G.E.); Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany (C.-H.H.); Translumina GmbH, Hechingen, Germany (B.B.); Department of Cardiothoracic Surgery, Stanford Cardiovascular Institute, Stanford University, CA (R.C.R., S.S.); Department of Cardiovascular Medicine, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA (J.M.S., P.S.T.); and Department of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University, CA (J.M.S., P.S.T.). schrepfer@stanford.edu.
Abstract
OBJECTIVE: Despite advances in stent technology for vascular interventions, in-stent restenosis (ISR) because of myointimal hyperplasia remains a major complication. APPROACH AND RESULTS: We investigated the regulatory role of microRNAs in myointimal hyperplasia/ISR, using a humanized animal model in which balloon-injured human internal mammary arteries with or without stenting were transplanted into Rowett nude rats, followed by microRNA profiling. miR-21 was the only significantly upregulated candidate. In addition, miR-21 expression was increased in human tissue samples from patients with ISR compared with coronary artery disease specimen. We systemically repressed miR-21 via intravenous fluorescein-tagged-locked nucleic acid-anti-miR-21 (anti-21) in our humanized myointimal hyperplasia model. As expected, suppression of vascular miR-21 correlated dose dependently with reduced luminal obliteration. Furthermore, anti-21 did not impede reendothelialization. However, systemic anti-miR-21 had substantial off-target effects, lowering miR-21 expression in liver, heart, lung, and kidney with concomitant increase in serum creatinine levels. We therefore assessed the feasibility of local miR-21 suppression using anti-21-coated stents. Compared with bare-metal stents, anti-21-coated stents effectively reduced ISR, whereas no significant off-target effects could be observed. CONCLUSION: This study demonstrates the efficacy of an anti-miR-coated stent for the reduction of ISR.
OBJECTIVE: Despite advances in stent technology for vascular interventions, in-stent restenosis (ISR) because of myointimal hyperplasia remains a major complication. APPROACH AND RESULTS: We investigated the regulatory role of microRNAs in myointimal hyperplasia/ISR, using a humanized animal model in which balloon-injured human internal mammary arteries with or without stenting were transplanted into Rowett nude rats, followed by microRNA profiling. miR-21 was the only significantly upregulated candidate. In addition, miR-21 expression was increased in human tissue samples from patients with ISR compared with coronary artery disease specimen. We systemically repressed miR-21 via intravenous fluorescein-tagged-locked nucleic acid-anti-miR-21 (anti-21) in our humanized myointimal hyperplasia model. As expected, suppression of vascular miR-21 correlated dose dependently with reduced luminal obliteration. Furthermore, anti-21 did not impede reendothelialization. However, systemic anti-miR-21 had substantial off-target effects, lowering miR-21 expression in liver, heart, lung, and kidney with concomitant increase in serum creatinine levels. We therefore assessed the feasibility of local miR-21 suppression using anti-21-coated stents. Compared with bare-metal stents, anti-21-coated stents effectively reduced ISR, whereas no significant off-target effects could be observed. CONCLUSION: This study demonstrates the efficacy of an anti-miR-coated stent for the reduction of ISR.
Authors: Jonathan G Godwin; Xupeng Ge; Kristin Stephan; Anke Jurisch; Stefan G Tullius; John Iacomini Journal: Proc Natl Acad Sci U S A Date: 2010-07-22 Impact factor: 11.205
Authors: Phong Trang; Jason F Wiggins; Christopher L Daige; Chris Cho; Michael Omotola; David Brown; Joanne B Weidhaas; Andreas G Bader; Frank J Slack Journal: Mol Ther Date: 2011-03-22 Impact factor: 11.454
Authors: Harry L A Janssen; Hendrik W Reesink; Eric J Lawitz; Stefan Zeuzem; Maribel Rodriguez-Torres; Keyur Patel; Adriaan J van der Meer; Amy K Patick; Alice Chen; Yi Zhou; Robert Persson; Barney D King; Sakari Kauppinen; Arthur A Levin; Michael R Hodges Journal: N Engl J Med Date: 2013-03-27 Impact factor: 91.245
Authors: Lars Maegdefessel; Joshua M Spin; Matti Adam; Uwe Raaz; Ryuji Toh; Futoshi Nakagami; Philip S Tsao Journal: Int J Mol Sci Date: 2013-07-11 Impact factor: 5.923
Authors: Robert A McDonald; Katie M White; Junxi Wu; Brian C Cooley; Keith E Robertson; Crawford A Halliday; John D McClure; Sheila Francis; Ruifaug Lu; Simon Kennedy; Sarah J George; Song Wan; Eva van Rooij; Andrew H Baker Journal: Eur Heart J Date: 2013-03-25 Impact factor: 29.983
Authors: Hong Jin; Daniel Y Li; Ekaterina Chernogubova; Changyan Sun; Albert Busch; Suzanne M Eken; Peter Saliba-Gustafsson; Hanna Winter; Greg Winski; Uwe Raaz; Isabel N Schellinger; Nancy Simon; Renate Hegenloh; Ljubica Perisic Matic; Maja Jagodic; Ewa Ehrenborg; Jaroslav Pelisek; Hans-Henning Eckstein; Ulf Hedin; Alexandra Backlund; Lars Maegdefessel Journal: Mol Ther Date: 2018-01-31 Impact factor: 11.454